Paper30739743
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet, 2019. Cited by 328 papers, by iCite.
Cite this record
ConductScience Library. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Papers, record 30739743. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30739743
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Breast Neoplasms | Major topic |
| Drug Administration Schedule | |
| Female | |
| Humans |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| MC_U137686858 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed | NIH RePORTER |
| 25351 | Cancer Research UK | United Kingdom | PubMed | PubMed | |
| MC_UU_12026/1 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| 21133 | Cancer Research UK | United Kingdom | PubMed | PubMed | |
| UL1 TR000371 | NCATS NIH HHS | United States | UL1TR000371 | PubMed and NIH | NIH RePORTER |
| MC_U137686850 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| 27691 | Cancer Research UK | United Kingdom | PubMed | PubMed |
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00798070 | Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients | Background | ClinicalTrials.gov | |
| NCT06190600 | Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy | Background | ClinicalTrials.gov | |
| NCT07521397 | Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study. | Background | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 31741891 | Improving chemotherapy outcome in early breast cancer. | https://conductscience.org/library/papers/31741891 | PubMed |
| Comment in | 32132126 | Shorter intervals and sequential administration of adjuvant chemotherapy are effective in reducing the 10-year risk of recurrence and death in early breast cancer women without detrimental effects. | https://conductscience.org/library/papers/32132126 | PubMed |
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11818200 | Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. | Eur J Cancer | 2002 | https://conductscience.org/library/papers/11818200 | PubMed |
| 2 | 12610183 | Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12610183 | PubMed |
| 3 | 12637460 | Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12637460 | PubMed |
| 4 | 15837983 | Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15837983 | PubMed |
| 5 | 15894097 | Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. | Lancet | 2005 | https://conductscience.org/library/papers/15894097 | PubMed |
| 6 | 18182617 | Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. | J Natl Cancer Inst | 2008 | https://conductscience.org/library/papers/18182617 | PubMed |
| 7 | 19103732 | Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19103732 | PubMed |
| 8 | 19364964 | Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19364964 | PubMed |
| 9 | 19901117 | Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/19901117 | PubMed |
| 10 | 20519679 | Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20519679 | PubMed |
| 11 | 22152853 | Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. | Lancet | 2012 | https://conductscience.org/library/papers/22152853 | PubMed |
| 12 | 22733553 | Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. | EMBO Mol Med | 2012 | https://conductscience.org/library/papers/22733553 | PubMed |
| 13 | 23940225 | Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23940225 | PubMed |
| 14 | 25422488 | SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25422488 | PubMed |
| 15 | 25740286 | Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. | Lancet | 2015 | https://conductscience.org/library/papers/25740286 | PubMed |
| 16 | 25919529 | Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. | JAMA | 2015 | https://conductscience.org/library/papers/25919529 | PubMed |
| 17 | 26077235 | Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26077235 | PubMed |
| 18 | 26211827 | Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. | Lancet | 2015 | https://conductscience.org/library/papers/26211827 | PubMed |
| 19 | 26940688 | Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. | Ann Oncol | 2016 | https://conductscience.org/library/papers/26940688 | PubMed |
| 20 | 27825007 | Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. | JAMA | 2016 | https://conductscience.org/library/papers/27825007 | PubMed |
Cited by199
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 328 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42967914 | Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS). | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42967914 | PubMed |
| 42938878 | Cardiovascular Magnetic Resonance for Early Detection of Cancer Therapy-Related Cardiac Dysfunction: From Multiparametric Tissue Signatures to Clinical Pathways. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938878 | PubMed |
| 42920438 | Case Report: Ribociclib-associated bilateral neurotrophic keratitis requiring amniotic membrane transplantation during adjuvant treatment of early breast cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42920438 | PubMed |
| 42826677 | Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: an exploratory analysis of the GIM2 trial. | Breast | 2026 | https://conductscience.org/library/papers/42826677 | PubMed |
| 42743833 | Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal. | Breast | 2026 | https://conductscience.org/library/papers/42743833 | PubMed |
| 42731007 | [Anthracycline use in breast cancer based on our current knowledge]. | Magy Onkol | 2026 | https://conductscience.org/library/papers/42731007 | PubMed |
| 42630843 | Cytoskeletal dynamics in breast cancer: mechanistic insights and therapeutic opportunities. | J Natl Cancer Cent | 2026 | https://conductscience.org/library/papers/42630843 | PubMed |
| 42602220 | Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42602220 | PubMed |
| 42544249 | Neoadjuvant Chemotherapy Response in Breast Cancer among Nigerian Women: A Systematic Review and Meta-Analysis (2000-2025). | Niger Med J | 2026 | https://conductscience.org/library/papers/42544249 | PubMed |
| 42528614 | Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42528614 | PubMed |
| 42500284 | Machine learning-based prognostic model for triple-negative breast cancer with axillary lymph node metastasis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42500284 | PubMed |
| 42364416 | Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial. | Breast | 2026 | https://conductscience.org/library/papers/42364416 | PubMed |
| 42279302 | Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Literature Overview. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279302 | PubMed |
| 42189890 | Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42189890 | PubMed |
| 42073623 | Impact of Neoadjuvant Chemotherapy Administration Time of Day on Pathological Response in Patients with Early Triple-Negative Breast Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42073623 | PubMed |
| 41959917 | Development and validation of a machine learning model for predicting unplanned removal of totally implantable venous access ports in patients with breast cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/41959917 | PubMed |
| 41949990 | Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis. | Ann Med | 2026 | https://conductscience.org/library/papers/41949990 | PubMed |
| 41832961 | Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. | JNCI Cancer Spectr | 2026 | https://conductscience.org/library/papers/41832961 | PubMed |
| 41782330 | Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer. | J Natl Cancer Inst | 2026 | https://conductscience.org/library/papers/41782330 | PubMed |
| 41754767 | Method-Comparison Validation of a Novel Capillary Blood Collection Kit, True Dose® TD-EPI, for Therapeutic Drug Monitoring of Epirubicin. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41754767 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30739743
GET https://conductscience.org/api/papers/v1/30739743/references?page=2